Bridgebio Entered into an Exclusive License Agreement with BMS to Develop and Commercialize BBP-398 for the Treatment of Cancer
May 13, 2022
BridgeBio Entered into an Asset Purchase Agreement with Sentynl to Commercilize Nulibry (fosdenopterin) for Molybdenum Cofactor De...
March 9, 2022
BridgeBio Reports First Patient Dosing in P-I/II (ADventure) Trial for the Treatment of Congenital Adrenal Hyperplasia
January 28, 2022
BridgeBio and Amgen Entered into a Non-Exclusive Clinical Collaboration for BBP-398 in P-I/II Study for Advanced Solid Tumors
January 14, 2022
PharmaShots Weekly Snapshots (July 26 - 30, 2021)
July 30, 2021
Insights+: The US FDA New Drug Approvals in May 2021
June 17, 2021
No more records!
Incisive News in 3 Shots.
First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2022 PharmaShots - All Rights Reserved.